Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 12, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback activity:
- Shares Purchased: 476,000 Ordinary Shares of 25 pence each.
- Transaction Date: June 12, 2013.
- Price Range: Highest price paid was 1,694.0 pence per share; lowest price paid was 1,661.5 pence per share.
- Treasury Holdings: Post-transaction, the company holds 509,044,512 shares in Treasury (9.38% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.37% of total voting rights.
- Shares in Issue: 4,920,477,444 shares (excluding Treasury shares).
Material Changes
The filing does not provide comparative financial data against prior periods. The material change reported is the reduction of outstanding shares through the repurchase of 476,000 shares, which are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,044,512) against the company's latest capital structure reports.
- Confirm the calculation of total voting rights (10.37% held in Treasury) for disclosure threshold assessments.
- Check the price paid per share (1,661.5 to 1,694.0 pence) against market trading prices on June 12, 2013.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for full financial results.